Chengdu Haibo Pharmaceutical

Chengdu Haibo Pharmaceutical is a China-based biotechnology company focused on the research and development of innovative small molecule drugs, particularly for metabolic and endocrine diseases. The company specializes in the discovery of novel treatments for type 2 diabetes, utilizing targets such as GPR119 and SGLT2 to improve glucose control and metabolic health. Chengdu Haibo Pharmaceutical operates a comprehensive R&D center in Chengdu, integrating medicinal chemistry, pharmacology, and clinical development capabilities. Its pipeline includes several proprietary candidates currently undergoing clinical and preclinical evaluation to address unmet needs in the chronic disease market.